Analysis of the target mechanism of adagrasib (Krazati) and summary of its advantages in precision therapy

Adagrasib (Adagrasib, trade name Krazati) is an oral KRAS G12C inhibitor developed by the American Mirati Therapeutics company. KRAS mutations are one of the most common driver mutations in non-small cell lung cancer, of which KRAS G12C mutations account for approximately 13% of all KRAS mutations. In the past, KRAS was considered an "undruggable" target due to its special structure. The emergence of adagrasib broke this situation and provided a new option for precision treatment.

Adagrasib selectively and irreversibly binds to the GDP binding state of the KRAS G12C mutant protein, locks the mutant protein in an inactive form and blocks its activation of the downstream MAPK/ERK signaling pathway, thereby inhibiting the proliferation and growth of tumor cells. The drug has a long half-life (about 24 hours) and good tissue penetration, including the central nervous system, making it also show some potential in controlling brain metastasis.

Compared with traditional chemotherapy, adagrasib has a higher objective response rate and more durable efficacy in patients with KRAS G12C mutations. In clinical trials, its objective response rate exceeded 40% and the disease control rate was as high as 80% in patients with advanced non-small cell lung cancer who had previously received standard treatment. In addition, oral administration is convenient and side effects are relatively controllable, bringing new treatment opportunities to advanced patients.

In the future, adagrasib is expected to play a greater role in combined immunotherapy, chemotherapy or other targeted drugs, improving the treatment response rate and delaying the occurrence of drug resistance. At the same time, as molecular testing becomes more popular and KRAS mutation screening becomes routine, more and more patients will benefit from this type of precision-targeted drugs. Adagarasib's unique pharmacokinetic characteristics and central nervous system activity make it occupy an important position in KRAS G12C targeted therapy in the era of precision medicine.

Reference link:https://www.drugs.com